SerImmune develops immune mapping technology to analyze immune responses. The company is based in Santa Barbara. A regulatory filing disclosed $1.4M in new funding for SerImmune. That $1.4M is described as part of an ongoing $7.0M funding effort. The filing shows the round as debt financing, suggesting it is likely convertible debt. No investors were named in the disclosure. SerImmune operates a platform that maps the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases, and cancers. The platform uses molecular libraries composed of billions of antigen decoys combined with big-data informatic tools to identify antibody–antigen relationships. Led by CEO Patrick Daugherty, the company maintains an antibody repertoire database to support therapeutic and diagnostic development. SerImmune raised $8M in funding to expand its immune mapping technology platform and antibody repertoire database. Investors included Illumina Ventures as lead, participation from Merck (MSD) through a subsidiary, and additional undisclosed investors. The company plans to use the proceeds to broaden platform capabilities and build strategic partnerships.

Total raised

$9M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Jun 2019